Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599310 | 0.86 | HCAR3 (0.65) | FGFR1HCAR3HPGDKMT2AGAA | |
| SCHEMBL16602284 | 0.86 | ALDH1A1 (0.53) | FGFR1TNKSTNKS2CHRNA7HPGD | |
| SCHEMBL29819602 | 0.86 | ALDH1A1 (0.53) | FGFR1TNKSTNKS2CHRNA7HPGD | |
| SCHEMBL11171 | 0.85 | SMN1; SMN2 (0.50) | FGFR1TNKSTNKS2CHRNA7HPGD | |
| Hydrochloric Acid SCHEMBL7330424 | 0.85 | HCAR3 (0.63) | FGFR1HCAR3HPGDKMT2AGAA | |
| SCHEMBL20570515 | 0.85 | CHRNA7 (0.47) | FGFR1TNKSTNKS2CHRNA7HPGD | |
| SCHEMBL12094844 | 0.82 | SMN1; SMN2 (0.48) | FGFR1TNKSTNKS2CHRNA7HPGD | |
| SCHEMBL3492748 | 0.82 | FGFR1 (0.53) | FGFR1CHRNA7HPGDKMT2ADYRK1A | |
| SCHEMBL29555125 | 0.82 | FGFR1 (0.53) | FGFR1CHRNA7HPGDKMT2ADYRK1A | |
| SCHEMBL10110841 | 0.82 | CHRNA7 (0.46) | FGFR1TNKSTNKS2CHRNA7HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122039051-A | Composite coating for high-wear-resistance sliding bearing and preparation method thereof | 成都工业职业技术学院 | 2026-05-15 | — | — | CN | claimed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| CN-122039051-A | Composite coating for high-wear-resistance sliding bearing and preparation method thereof | 成都工业职业技术学院 | 2026-05-15 | — | — | CN | disclosed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| EP-4688144-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| WO-2011057054-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | VITAE PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | THE PROCTER & GAMBLE COMPANY | 2004-01-08 | — | — | US | disclosed |
| US-6410529-B1 | DIETETICS; NON-INSULIN DEPENDENT DIABETES; SLEEP DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| WO-2002016327-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS NEUTROPHIL INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-0376624-B1 | 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation | YAMANOUCHI PHARMA CO LTD (JP) | 1994-09-14 | — | — | EP | disclosed |
| WO-1992022536-A1 | VINYLIMIDAZOLES, VINYLTRIAZOLES AND VINYLTETRAZOLES WITH A BICYCLIC SUBSTITUENT GROUP | SCHERING AKTIENGESELLSCHAFT, BERLIN UND BERGKAMEN (DE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518457-A1 | Bicyclic substituted vinylimidazoles, -triazoles and -tetrazoles | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-16 | — | — | EP | disclosed |
| US-4977175-A | GASTROINTESTINAL DISORDERS, ANTIEMETICS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-12-11 | — | — | US | disclosed |
| EP-0376624-A1 | 4,5,6,7-Tetrahydrobenzimidazole derivatives and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | FGFR1 1689/4885HCAR3 117/4885TNKS 1787/4885 |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | GLP1R, GIPR, GCGR | FGFR1 53/4885HCAR3 128/4885TNKS 4076/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | FGFR1 210/4885HCAR3 215/4885TNKS 4340/4885 |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | FGFR1 39/4885HCAR3 122/4885TNKS 3929/4885 |
| US-20040006104-A1 | Neutrophil inhibitors to reduce inflammatory response | MPO, SERPINB1, NCF1 | FGFR1 2126/4885HCAR3 379/4885TNKS 1327/4885 |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | FGFR1 59/4885HCAR3 108/4885TNKS 4192/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | FGFR1 1898/4885HCAR3 532/4885TNKS 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.